WHO ICTRP trial
TRINOVA-2: TRial IN OVArian Cancer-2
EUCTR2009-017946-30-HU · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-017946-30-HU |
|---|---|
| Public title | TRINOVA-2: TRial IN OVArian Cancer-2 |
| Scientific title | A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - TRINOVA-2 |
| Primary sponsor | Amgen Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | United States;Taiwan;Hong Kong;Slovakia;Greece;Spain;Austria;Italy;United Kingdom;France;Hungary;European Union;Canada;Poland;Belgium;Singapore;Denmark;Australia;Latvia;Germany;New Zealand |
| Conditions | Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer MedDRA version: 17.0 Level: PT Classification code 10066697 Term: Ovarian cancer recurrent System Organ Class: 10029104… |
| Interventions | Product Name: AMG 386 Product Code: AMG 386 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trebananib Current Sponsor code: AMG 386 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal… |
| Registration date | Nov 23, 2010 |
| Target size | 223 |
| Secondary IDs | 20060517;NCT01281254 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: